Get the Stockscreener App
35.58
1.45%
0.51
Livanova Plc stock is traded at $35.58, with a volume of 614.57K.
It is up +1.45% in the last 24 hours and down -14.08% over the past month.
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
See More
Previous Close:
$35.07
Open:
$34.13
24h Volume:
614.57K
Relative Volume:
0.89
Market Cap:
$1.93B
Revenue:
$1.24B
Net Income/Loss:
$23.68M
P/E Ratio:
84.71
EPS:
0.42
Net Cash Flow:
$108.67M
1W Performance:
+4.22%
1M Performance:
-14.08%
6M Performance:
-33.15%
1Y Performance:
-31.41%
1-Day Range:
$34.00
$35.69
1-Week Range:
$32.65
$35.88
52-Week Range:
$32.48
$64.47
Livanova Plc Stock (LIVN) Company Profile
Name
Livanova Plc
Sector
Industry
Phone
4402033250662
Address
20 EASTBOURNE TERRACE, LONDON
Compare LIVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
35.58 | 1.93B | 1.24B | 23.68M | 108.67M | 0.42 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-04-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-20-24 | Reiterated | Needham | Buy |
| Feb-20-24 | Upgrade | Mizuho | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Feb-24-22 | Upgrade | UBS | Neutral → Buy |
| Dec-03-21 | Initiated | Goldman | Buy |
| Aug-20-21 | Reiterated | Needham | Buy |
| Jul-20-21 | Upgrade | Needham | Hold → Buy |
| Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
| Jan-05-21 | Downgrade | Needham | Buy → Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-26-20 | Reiterated | Needham | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-08-18 | Initiated | Stifel | Buy |
| May-31-18 | Reiterated | Needham | Buy |
| Feb-28-18 | Reiterated | Needham | Buy |
View All
Livanova Plc Stock (LIVN) Latest News
Mizuho Adjusts Price Target for LivaNova (LIVN) Ahead of Q1 Preview | LIVN Stock News - GuruFocus
What Is LivaNova PLC's (NASDAQ:LIVN) Share Price Doing? - Yahoo Finance
LivaNova PLC (LIVN): Among the Best UK Stocks to Buy According to Billionaires - Insider Monkey
Cardiovascular Devices Market Demand, Growth and Future Scope - openPR.com
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For - simplywall.st
Aortic Stenosis Market to Witness Massive Growth by 2032 | - openPR.com
10 Best UK Stocks to Buy According to Billionaires - Insider Monkey
LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns (LIVN) - Seeking Alpha
LivaNova stock plunges to 52-week low, touches $36.18 By Investing.com - Investing.com Canada
LivaNova stock plunges to 52-week low, touches $36.18 - Investing.com Australia
Vagus Nerve Stimulators Market Size, Growth Trends and Report - openPR.com
(LIVN) Trading Advice - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Bought by Prudential Financial Inc. - MarketBeat
Implantable Cardioverter Defibrillators Market to Witness - openPR.com
LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com - MarketBeat
LivaNova to Announce First-Quarter 2025 Results - Sharewise
LivaNova Q1 2025 Earnings Preview: Your Essential Guide to May 7 Financial Results - Stock Titan
LivaNova (NASDAQ:LIVN) investors are sitting on a loss of 50% if they invested three years ago - Yahoo Finance
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now? - simplywall.st
LivaNova PLC (LIVN) Shares Up 0.4% on Mar 19 - GuruFocus.com
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight - The Globe and Mail
Vagus Nerve Stimulators Market is Expected to Witness Positive - openPR
Jefferies cuts Livanova stock price target to $74 from $80 - Investing.com India
Barclays maintains Livanova stock with $56 target, cites clarity By Investing.com - Investing.com South Africa
Jefferies cuts Livanova stock price target to $74 from $80 By Investing.com - Investing.com Australia
LivaNova to record $363 million liability after court ruling By Investing.com - Investing.com Australia
Needham maintains Livanova buy rating, $64 target amid liability By Investing.com - Investing.com Australia
Barclays Maintains Livanova (LIVN) at Equalweight - StreetInsider.com
Barclays Starts Livanova (LIVN) at Equalweight - StreetInsider
Needham maintains Livanova buy rating, $64 target amid liability - Investing.com
LivaNova to record $363 million liability after court ruling - Investing.com
LivaNova Faces €333 Million Liability Ruling - TipRanks
Supreme Court Rules LivaNova Not Liable For 157 Mln Euros Payments In Environmental Liabilities Case - Marketscreener.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles - Investing.com Australia
Cardiovascular Devices Market Booming with Technological - openPR
Autotransfusion Devices and Consumables Market is Estimated - openPR
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles By Investing.com - Investing.com South Africa
LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of New York Mellon Corp - Defense World
Vagus Nerve Stimulators Market Generated Opportunities, - openPR
LivaNova at Barclays Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
LivaNova at Barclays Conference: Strategic Growth and Innovation - Investing.com India
When the Price of (LIVN) Talks, People Listen - Stock Traders Daily
Goldman Sachs maintains Livanova buy rating, $55 target By Investing.com - Investing.com UK
Barclays Cuts LivaNova (NASDAQ:LIVN) Price Target to $56.00 - Defense World
Mutual of America Capital Management LLC Sells 663 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
Livanova PLC to Host Earnings Call - ACCESS Newswire
Livanova Plc Stock (LIVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Livanova Plc Stock (LIVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
| KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
| Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
| Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
| Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
| Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
| Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
| Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
| Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
| Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):